EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Pamrevlumab for Idiopathic Pulmonary Fibrosis

Ganesh Raghu, Luca Richeldi, Evans R Fernández Pérez, Maria Cristina De Salvo, Rafael S Silva, Jin Woo Song, Takashi Ogura, Zuo Jun Xu, Elizabeth A Belloli, Xueping Zhang, Lorilyn L Seid, Lona Poole und 1 weitere

JAMA · 06.08.2024 · 332 (5) · 380

DOI: 10.1001/jama.2024.8693 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 06.08.2024. Verfasst von Ganesh Raghu und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Current treatments for idiopathic pulmonary fibrosis slow the rate of lung function decline, but may be associated with adverse events that affect medication adherence. In phase 2 trials, pamrevlumab (a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor activity) attenuated the progression of idiopathic pulmonary fibrosis without substantial adverse events.

Objective

To assess the efficacy and safety of pamrevlumab for patients with idiopathic pulmonary fibrosis. Design, Setting, and Participants Phase 3 randomized clinical trial including 356 patients aged 40 to 85 years with idiopathic pulmonary fibrosis who were not receiving antifibrotic treatment with nintedanib or pirfenidone at enrollment. Patients were recruited from 117 sites in 9 countries between July 18, 2019, and July 29, 2022; the last follow-up encounter occurred on August 28, 2023.

Interventions

Pamrevlumab (30 mg/kg administered intravenously every 3 weeks; n = 181) or placebo (n = 175) for 48 weeks. Main Outcomes and Measures The primary outcome was absolute change in forced vital capacity (FVC) from baseline to week 48. There were 5 secondary outcomes (including time to disease progression, which was defined as a decline of ≥10% in predicted FVC or death). The exploratory outcomes included patient-reported symptoms. Adverse events were reported.

Results

Among 356 patients (mean age, 70.5 years; 258 [72.5%] were men; 221 [62.1%] were White), 277 (77.8%) completed the trial. There was no significant between-group difference for absolute change in FVC from baseline to week 48 (least-squares mean, −260 mL [95% CI, −350 to −170 mL] in the pamrevlumab group vs −330 mL [95% CI, −430 to −230 mL] in the placebo group; mean between-group difference, 70 mL [95% CI, −60 to 190 mL], P = .29). There were no significant between-group differences in any of the secondary outcomes or in the patient-reported outcomes. In the pamrevlumab group, there were 160 patients (88.4%) with treatment-related adverse events and 51 patients (28.2%) with serious adverse events vs 151 (86.3%) and 60 (34.3%), respectively, in the placebo group. During the study, 23 patients died in each group (12.7% in the pamrevlumab group vs 13.1% in the placebo group). Conclusions and Relevance Among patients with idiopathic pulmonary fibrosis treated with pamrevlumab or placebo, there was no statistically significant between-group difference for the primary outcome of absolute change in FVC from baseline to week 48. Trial Registration ClinicalTrials.gov Identifier: NCT03955146

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedIdiopathic Pulmonary FibrosisAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedConnective Tissue Growth FactorDisease ProgressionDouble-Blind MethodVital CapacityInfusions, IntravenousPatient Reported Outcome Measures

Substanzen

Antibodies, Monoclonal, HumanizedConnective Tissue Growth Factorpamrevlumab

Autor:innen und Institutionen

  • University of Washington, Seattle.
  • Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
  • National Jewish Health, Denver, Colorado.
  • Fundacion Respirar-Centro Médico, Buenos Aires, Argentina.
  • Hospital Regional de Talca, Maule, Chile.
  • Asan Medical Center, College of Medicine, University of Ulsan, Seoul, South Korea.

Zitieren

APA

Raghu, G., Richeldi, L., Fernández Pérez, E. R., De Salvo, M. C., Silva, R. S., Song, J. W., Ogura, T., Xu, Z. J., Belloli, E. A., Zhang, X., Seid, L. L., Poole, L., & ZEPHYRUS-1 Study Investigators (2024). Pamrevlumab for Idiopathic Pulmonary Fibrosis. JAMA, 332(5), 380. https://doi.org/10.1001/jama.2024.8693

Vancouver

Raghu G, Richeldi L, Fernández Pérez ER, De Salvo MC, Silva RS, Song JW, et al. Pamrevlumab for Idiopathic Pulmonary Fibrosis. JAMA. 2024;332(5):380. doi:10.1001/jama.2024.8693

BibTeX
@article{Raghu2024,
  author = {Raghu, Ganesh and Richeldi, Luca and Fernández Pérez, Evans R and De Salvo, Maria Cristina and Silva, Rafael S and Song, Jin Woo and Ogura, Takashi and Xu, Zuo Jun and Belloli, Elizabeth A and Zhang, Xueping and Seid, Lorilyn L and Poole, Lona and ZEPHYRUS-1 Study Investigators, ZEPHYRUS-1 Study Investigators},
  title = {Pamrevlumab for Idiopathic Pulmonary Fibrosis},
  journal = {JAMA},
  year = {2024},
  volume = {332},
  number = {5},
  pages = {380},
  doi = {10.1001/jama.2024.8693}
}
Kostenlos starten →